荣新奇, 武明胜, 辛学知, 张波, 刘佃温, 肖慧荣, 王振宜, 崔焌辉, 王建平, 王忠诚, 范小华, 胡莹, 荣奕盛, 李盈. 九华痔疮栓联合地奥司明片治疗痔疮出血的有效性和安全性:一项多中心、随机对照试验[J]. Digital Chinese Medicine, 2023, 6(4): 467-476. DOI: 10.1016/j.dcmed.2024.01.009
引用本文: 荣新奇, 武明胜, 辛学知, 张波, 刘佃温, 肖慧荣, 王振宜, 崔焌辉, 王建平, 王忠诚, 范小华, 胡莹, 荣奕盛, 李盈. 九华痔疮栓联合地奥司明片治疗痔疮出血的有效性和安全性:一项多中心、随机对照试验[J]. Digital Chinese Medicine, 2023, 6(4): 467-476. DOI: 10.1016/j.dcmed.2024.01.009
Citation: RONG XQ, WU MS, XIN XZ, et al. Efficacy and safety of Jiuhua hemorrhoid suppository plus diosmin for the treatment of hemorrhoid hemorrhage: a multicenter, randomized, and controlled trial. Digital Chinese Medicine, 2023, 6(4): 467-476. DOI: 10.1016/j.dcmed.2024.01.009
Citation: Citation: RONG XQ, WU MS, XIN XZ, et al. Efficacy and safety of Jiuhua hemorrhoid suppository plus diosmin for the treatment of hemorrhoid hemorrhage: a multicenter, randomized, and controlled trial. Digital Chinese Medicine, 2023, 6(4): 467-476. DOI: 10.1016/j.dcmed.2024.01.009

九华痔疮栓联合地奥司明片治疗痔疮出血的有效性和安全性:一项多中心、随机对照试验

Efficacy and safety of Jiuhua hemorrhoid suppository plus diosmin for the treatment of hemorrhoid hemorrhage: a multicenter, randomized, and controlled trial

  • 摘要:
    目的 比较地奥司明片联合九华痔疮栓与地奥司明片单独治疗痔疮出血的疗效和安全性。
    方法 九华痔疮栓的研究于2019年4月至2020年6月在中国的10所医院进行。痔疮出血患者按1∶1随机分组接受九华痔疮栓联合地奥司明片治疗(试验组)或地奥司明片单药治疗(对照组)。痔疮栓在排便后或睡前用温水冲洗肛门后使用,每天一次。地奥司明片(0.9 g)每天口服一次。主要终点为治疗7 ± 2天后痔疮出血的缓解情况,分为“非常有效”“有效”和“无效”。次要终点包括疼痛使用视觉模拟量表(VAS)评估,评分范围为0 − 10和水肿(评分范围为0 − 3)的缓解情况。治疗14 ± 2天后评估两组的安全性。
    结果 全分析集(FAS)包括试验组107例和对照组111例受试者,符合方案集(PPS)则分别包括106和111例受试者。对于痔疮出血的疗效,FAS集中试验组评估为非常有效/有效的病例比例显著高于对照组 106 (99.06%) vs. 91 (81.98%),P < 0.0001,PPS集的结果 105 (99.06%) vs. 91 (81.98%), P < 0.000 1 与FAS集类似。治疗7天后两组的VAS疼痛评分相似(0.80 ± 1.17 vs. 0.80 ± 1.20,P = 0.2177)。两组中大多数受试者在治疗7天后的水肿评分为0 96 (89.72%) vs. 99 (91.67%),P = 0.3705。试验组9例(8.4%)和对照组3例(2.7%)受试者发生不良事件(AEs)。两组分别有5例和1例AEs被判定为可能与研究药物有关。
    结论 与单独服用地奥司明片相比,加用九华痔疮栓对痔疮出血的效果更好。患者的依从性满意,安全性可耐受。

     

    Abstract:
    Objective To compare the efficacy and safety of combining diosmin with Jiuhua hemorrhoid suppository versus diosmin alone for the treatment of hemorrhoid hemorrhage.
    Methods The Jiuhua hemorrhoid suppository study was conducted in 10 medical centers across China from April 1, 2019 to June 30, 2020. Patients with hemorrhoid bleeding were randomized in a ratio of 1 : 1 to either receive Jiuhua hemorrhoid suppository and diosmin tablets (the study group) or diosmin tablets alone (the control group). The suppository was used once a day after defecation or at bedtime after rinsing the anus with warm water. Diosmin tablets were administered only once a day (0.9 g). The primary endpoint of the study was the assessment of hemorrhoid bleeding relief 7 ± 2 days after treatment, classified as “very effective” “effective” and “ineffective”. The secondary endpoint included the evaluation of pain alleviation using the visual analogue scale (VAS, with scores ranging from 0 to 10) and edema (with scores ranging from 0 to 3). The safety of the two treatment regimens was evaluated 14 ± 2 days after drug administration.
    Results The full analysis set (FAS) comprised 107 participants in the study group and 111 in the control group, while the per-protocol set (PPS) included 106 participants in the study group and 111 in the control group. In terms of hemorrhoid bleeding, the proportion of very effective and effective cases in the study group were significantly higher than that in the control group 106 (99.06%) vs. 91 (81.98%), P < 0.0001 in the FAS, and the PPS results 105 (99.06%) vs. 91 (81.98%), P < 0.0001 were comparable to the FAS results. The pain VAS scores at day 7 after treatment were comparable between the two groups (0.80 ± 1.17 vs. 0.80 ± 1.20, P = 0.2177). The majority of the participants in both groups had an edema score of 0 at day 7 after treatment 96 (89.72%) vs. 99 (91.67%), P = 0.3705. Adverse events (AEs) occurred in 9 patients (8.4%) in the study group and 3 patients (2.7%) in the control group. In addition, 5 AEs in the study group and 1 AE in the control group were possibly in association with the study drug.
    Conclusion Compared with the administration of diosmin oral tablets alone, the addition of Jiuhua hemorrhoid suppository to the tablets demonstrates enhanced efficacy in addressing hemorrhoid bleeding, with satisfactory patient adherence and acceptable safety.

     

/

返回文章
返回